Research from industry analyst GlobalData shows that acquisitions of contract manufacturing organizations (CMOs) are increasing at a significant rate.
Private equity firms are most commonly behind such purchases, with strong growth in the sector bolstering the potential for a reliable return on investment.
In its report GlobalData finds that private equity companies bought almost 70 pharmaceutical CMOs during the two-year period from 2018 to 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze